David Hudesman
Overview
Explore the profile of David Hudesman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
1361
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hudesman D
Gastroenterol Hepatol (N Y)
. 2023 Sep;
19(8):475-477.
PMID: 37772156
No abstract available.
12.
Hudesman D, Long M, Wolf D, Hanauer S, Ghosh S, Petersen A, et al.
Am J Gastroenterol
. 2023 Jul;
116(Suppl 1):S9.
PMID: 37461954
Background: True North is a phase 3, randomized, double-blind, placebo-controlled trial conducted at 285 sites in 30 countries (NCT02435992). Treatment with once-daily ozanimod (an oral sphingosine 1-phosphate [S1P] receptor modulator...
13.
Fernandez C, Gajic Z, Esen E, Remzi F, Hudesman D, Adhikari S, et al.
Am J Gastroenterol
. 2023 Jul;
118(12):2230-2241.
PMID: 37410929
Introduction: Older adults with inflammatory bowel disease (IBD) are at higher risk for postoperative complications as compared to their younger counterparts; however, factors contributing to this are unknown. We assessed...
14.
Stone K, Kulekofsky E, Hudesman D, Kozloff S, Remzi F, Axelrad J, et al.
Therap Adv Gastroenterol
. 2023 May;
16:17562848231158231.
PMID: 37124374
Background: The COVID-19 pandemic led to the urgent implementation of telehealth visits in inflammatory bowel disease (IBD) care; however, data assessing feasibility remain limited. Objectives: We looked to determine the...
15.
Walshe M, Borowski K, Battat R, Hudesman D, Wolf D, Okada L, et al.
Crohns Colitis 360
. 2023 Feb;
3(3):otab032.
PMID: 36776648
Background: Optimal ustekinumab levels (UST) in Crohn disease (CD) treatment have not been defined. We set out to define the optimal UST to differentiate between remission and active CD, as...
16.
Chang S, Hong S, Hudesman D, Remzi F, Sun K, Cao W, et al.
Inflamm Bowel Dis
. 2023 Jan;
29(11):1769-1777.
PMID: 36702534
Background: The prognostic significance of histology in ileal pouch-anal anastomosis (IPAA) remains unclear. The aim of this study was to evaluate if histologic variables are predictive of IPAA clinical outcomes...
17.
Johnson A, Barsky M, Ahmed W, Zullow S, Galati J, Jairath V, et al.
Am J Gastroenterol
. 2022 Oct;
118(2):317-328.
PMID: 36191274
Introduction: We evaluated the real-world effectiveness and safety of ustekinumab (UST) in patients with Crohn's disease (CD). Methods: This study used a retrospective, multicenter, multinational consortium of UST-treated CD patients....
18.
Faye A, Lee K, Dodson J, Chodosh J, Hudesman D, Remzi F, et al.
Aliment Pharmacol Ther
. 2022 Jul;
56(7):1157-1167.
PMID: 35879231
Background: Venous thromboembolism (VTE) is a significant cause of morbidity and mortality among patients with inflammatory bowel disease (IBD). However, data on national trends remain limited. Aims: To assess national...
19.
Long M, Afzali A, Fischer M, Hudesman D, Abdalla M, McCabe R, et al.
Inflamm Bowel Dis
. 2022 Jun;
29(4):570-578.
PMID: 35700276
Background: Tofacitinib is an oral, small-molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Using a novel electronic reporting tool, we aimed to prospectively describe the onset of tofacitinib...
20.
Dulai P, Rai V, Raffals L, Lukin D, Hudesman D, Kochhar G, et al.
Am J Gastroenterol
. 2022 Apr;
117(8):1288-1295.
PMID: 35416799
Introduction: Limited guidance exists for the postdischarge care of patients with ulcerative colitis hospitalized for moderate-severe flares. Methods: RAND methodology was used to establish appropriateness of inpatient and postdischarge steroid...